Focusing On The Bigger Picture At The EMA
Top Agency Exec Talks Life Beyond Brexit And Coronavirus
Tony Humphreys of the European Medicines Agency explains the thinking behind the agency’s regulatory science strategy, why the PRIME scheme is to get a boost, and why the need to tackle health threats ranked so low in a stakeholder consultation.
You may also be interested in...
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.
Coronavirus Update: Setback With Hydroxychloroquine, Slowdown In UK ADR Reports, But Novel Drugs Begin Trials
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.